TABLE 1.

Subject demographics and baseline characteristics

Parameter	Value in trial 1 with:a						Value in trial 2 with:a
	MHAA4549A					Placebo	MHAA4549A			Placebo
	1.5 mg/kg	5 mg/kg	15 mg/kg	45 mg/kg	Overall		8,400 mg	10,800 mg	Overall
No. of subjects randomized	4	4	4	4	16	5	4	4	8	6
Age (yr)	43 ± 7a	41 ± 12	43 ± 14	40 ± 24	41 ± 14	51 ± 15	41 ± 15	34 ± 3	37 ± 11	49 ± 12
No. of female subjects (%)	3 (75)	2 (50)	3 (75)	2 (50)	10 (63)	4 (80)	2 (50)	2 (50)	4 (50)	3 (50)
No. of White subjects (%)	4 (100)	4 (100)	4 (100)	4 (100)	16 (100)	5 (100)	4 (100)	4 (100)	8 (100)	6 (100)
Height (cm)	166 ± 14	165 ± 5	166 ± 15	167 ± 3	166 ± 10	164 ± 5	163 ± 9	168 ± 6	166 ± 7	168 ± 5
Weight (kg)	63 ± 17	75 ± 9	66 ± 7	65 ± 7	67 ± 11	65 ± 3	69 ± 9	69 ± 9	69 ± 8	75 ± 11
BMI (kg/m2)	23 ± 2	28 ± 3	24 ± 4	23 ± 3	25 ± 3	24 ± 1	26 ± 3	24 ± 3	25 ± 3	27 ± 4

^aValues are means ± SD unless otherwise noted. Trial 1, entry-into-human study; trial 2, high-dose study.